INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01801 INNOVENT BIO

Closed 03-16 16:08:22

84.100

+3.250

+4.02%

High84.450	Low79.600	Vol11.14M
Open80.850	D1 Closing80.850	Amplitude6.00%
Mkt Cap145.91B	Tradable Cap145.91B	Total Shares1.74B
T/O921.65M	T/O Rate0.64%	Tradable Shares1.74B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":84.1,"timestamp":1773648502003,"preClose":80.85,"halted":0,"volume":11140996,"delay":0,"changeRate":0.04019789734075448,"floatShares":1735000000,"shares":1735000000,"eps":-0.06,"marketStatus":"Closed","change":3.25,"latestTime":"03-16 16:08:22","open":80.85,"high":84.45,"low":79.6,"amount":921651866,"amplitude":0.059988,"askPrice":84.1,"askSize":33000,"bidPrice":84.05,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":0.739283,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":80.85,"openAndCloseTimeList":[[1773624600000,1773633600000],[1773637200000,1773648000000]],"volumeRatio":0.954246,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4927,"impliedVolPercentile":0.2764},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2618184384","title":"Innovent Biologics board to review annual results and consider final dividend recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184384","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618184384?lang=en_us&edition=fundamental","pubTime":"2026-03-12 16:35","pubTimestamp":1773304535,"startTime":"0","endTime":"0","summary":"Innovent Biologics will hold a board meeting on March 26, 2026 to consider and approve its annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2Tn5xB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","BK1147","LU2097828631.EUR","LU2097828805.USD","LU1969619763.USD","BK1583","BK1589","BK1161","LU0455707207.USD","LU2097828714.EUR","LU2328871848.SGD","01911","HK0000165453.HKD","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","01801","LU2242644610.SGD"],"gpt_icon":0},{"id":"1108655208","title":"Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1108655208","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108655208?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:28","pubTimestamp":1772807329,"startTime":"0","endTime":"0","summary":"The global weight-loss drug market is entering a new phase, driven by the launch of oral formulations, upcoming generic competition, and price reductions in the United States for blockbuster products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","BK4550","LU2097828631.EUR","LU2242644610.SGD","01801","LU0122379950.USD","LU0502904849.HKD","LU2097828557.USD","LU0306807586.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU1066051498.USD","PFE","LU1066053197.SGD","SG9999011175.SGD","SG9999013999.USD","IE00BLSP4239.USD","LU1023059063.AUD","NVO","BK4568","LU0321505439.SGD","IE00B19Z3581.USD","BK4592","IE0002270589.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK1583","LLY","SGXZ57979304.SGD","LU2097828474.EUR","LU2328871848.SGD","BK4007","BK1589","SG9999003800.SGD","LU0868494617.USD","LU0170899867.USD","IE00BBT3K403.USD","RHHBY","BK4585","HK0000165453.HKD","LU1057294990.SGD","LU1894683264.USD","LU2097828805.USD","LU0289739699.SGD","LU1883839398.USD","LU0225284248.USD","LU0456855351.SGD","SG9999001176.SGD","BK1161","LU0321505868.SGD","LU1894683348.USD","VKTX","SG9999002232.USD","MRK","LU2488822045.USD","BK4581","LU2097828714.EUR","BK4533","000963","SG9999001176.USD","IE000M9KFDE8.USD","LU0058720904.USD","AZN","LU0225771236.USD","LU1969619763.USD","BK4588","BK4599","BK4534","LU0306806265.USD","LU0234572021.USD"],"gpt_icon":1},{"id":"1115207358","title":"Biopharma Stocks Rally as Sector Gains Strategic \"Emerging Pillar\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1115207358","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115207358?lang=en_us&edition=fundamental","pubTime":"2026-03-06 10:14","pubTimestamp":1772763264,"startTime":"0","endTime":"0","summary":"Innovative drug stocks strengthened during the morning session. At the time of writing, HUTCHMED (00013) rose 9.02% to HK$22.96; 3SBIO (01530) increased 8.41% to HK$21.4; HENGRUI PHARMA (01276)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","BK1593","BK1589","BK4588","159992","BK1574","LU2097828714.EUR","LU2097828805.USD","BK1588","LU0455707207.USD","02162","BK1191","BK1587","01801","161726","LU0359201885.HKD","BK1161","LU1023057109.AUD","LABU","LU2097828474.EUR","LU2328871848.SGD","LU2543165471.USD","BK1583","VT","399441","LU1969619763.USD","LU2488822045.USD","01530","LU2097828631.EUR","VXUS","BK4585","06978","LU0359201612.USD","HK0000165453.HKD","LU0502904849.HKD","01276","LU2097828557.USD","00013","LU2242644610.SGD"],"gpt_icon":0},{"id":"1197012654","title":"INNOVENT BIO (01801) Announces Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1197012654","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197012654?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:44","pubTimestamp":1772714680,"startTime":"0","endTime":"0","summary":"Innovent Biologics, Inc. submitted its monthly return for February 2026 on 05 March 2026. The authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"1113303533","title":"JPMorgan Chase Increases Stake in INNOVENT BIO (01801) by Approximately 408.6 Thousand Shares at HK$84.94 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1113303533","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113303533?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:04","pubTimestamp":1772708660,"startTime":"0","endTime":"0","summary":"On February 27, JPMorgan Chase purchased an additional 408,630 shares of INNOVENT BIO (01801) at a price of HK$84.9352 per share. The total transaction value amounted to approximately HK$34.71...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0820561818.USD","SG9999002224.SGD","LU2237443895.HKD","LU2746668974.SGD","LU1267930490.SGD","LU0882574139.USD","IE00BDRTCR15.USD","LU1261432733.SGD","IE0034235295.USD","LU1366192091.USD","BK4581","LU2552382058.USD","BK4588","HK0000165453.HKD","LU2023250504.SGD","IE000M9KFDE8.USD","LU2381873111.SGD","LU2237443549.SGD","LU2237443622.USD","LU1244550221.USD","IE00BFXG1179.USD","LU0203345920.USD","LU2237443382.USD","LU0942090050.USD","LU1720051108.HKD","LU2023250330.USD","LU2242649171.HKD","LU1629891620.HKD","LU0964807845.USD","LU0265550946.USD","LU2097828714.EUR","LU0234572021.USD","LU0310799852.SGD","LU0215105999.USD","LU0323591593.USD","BK4534","LU0211328371.USD","LU1974910355.USD","IE00B775SV38.USD","LU1894683348.USD","LU2456880835.USD","BK4566","LU0006306889.USD","LU0787776722.HKD","BK1583","LU2552382132.HKD","IE0034235303.USD","LU2097828557.USD","LU0320765489.SGD","LU0971096721.USD","IE00B3S45H60.SGD","LU2462157665.USD","LU0496365809.HKD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU0106261372.USD","LU1548497426.USD","LU1969619763.USD","LU2357305700.SGD","LU0208291251.USD","JPMO","LU0868494617.USD","IE00BKVL7J92.USD","LU1145028129.USD","LU2505996509.AUD","LU0455707207.USD","LU1116320901.HKD","IE00BHPRN162.USD","LU1668664300.SGD","LU0070302665.USD","LU2552382215.SGD","LU0820562030.AUD","01801","BK4533","LU1551013425.SGD","LU0211326839.USD","LU2211815571.USD","LU1280957306.USD","LU1914381329.SGD","LU2236285917.USD","BK1589","BK4516","LU0345769631.USD","LU0345769128.USD","LU0106831901.USD","LU1116320737.USD","IE00BBT3K403.USD","LU0048584097.USD","LU0203347892.USD","LU1119994496.HKD","LU2430703251.USD","IE00BKDWB100.SGD","LU0211327993.USD","LU0868494708.USD","LU2106854487.HKD","IE00BWXC8680.SGD","LU2505996681.GBP","LU1162221912.USD","IE00BZ1G4Q59.USD","IE00BN8TJ469.HKD","IE00BLSP4239.USD","LU0170899867.USD","LU0251132253.USD","JPM","LU2213496289.HKD","IE00B1XK9C88.USD","LU2756315318.SGD","IE00BYXW3230.USD","LU1363072403.SGD","LU1064131342.USD","LU0345770308.USD","IE0034235188.USD","LU2430703178.SGD","LU0267386448.USD","LU0211326755.USD","LU2264538146.SGD","LU1720051017.SGD","LU0256863811.USD","LU2417539215.USD","LU0689472784.USD","LU2054465674.USD","LU2097828474.EUR","LU2488822045.USD","LU0976567544.SGD","LU1496350502.SGD","LU2237443465.HKD","LU0640476718.USD","LU1244550577.SGD","LU2328871848.SGD","LU1988902786.USD","BK4585","LU1670628061.USD","LU2746668461.USD","LU2237443978.SGD","LU0943347566.SGD","LU0320765646.SGD","LU1084165304.USD","LU1917777945.USD","LU0149725797.USD","LU1551013342.USD","LU0683600562.USD","LU2023250843.SGD","LU2592432038.USD","IE00BJTD4N35.SGD","LU2756315664.SGD","BK4550","LU1032466523.USD","LU2430703095.HKD","LU0345770993.USD","LU2097828631.EUR","LU1670627923.USD","BK4207","LU0417517546.SGD","BK4504","LU0211331839.USD","LU1496350171.SGD","LU1894683264.USD","LU2242644610.SGD","LU0238689110.USD","IE00BDCRKT87.USD","LU0820561909.HKD","SG9999002232.USD","LU0265550359.USD","IE00BJLML261.HKD","LU2097828805.USD","LU1244550494.USD","IE00BJTD4V19.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"1150296848","title":"Morgan Stanley Reinitiates Coverage on Innovent Bio with \"Overweight\" Rating, Sees Biotech Catalysts Concentrated in Second Half","url":"https://stock-news.laohu8.com/highlight/detail?id=1150296848","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150296848?lang=en_us&edition=fundamental","pubTime":"2026-03-04 11:20","pubTimestamp":1772594422,"startTime":"0","endTime":"0","summary":"Morgan Stanley has issued a research report announcing the reinitiation of coverage on Innovent Bio (01801) with an \"Overweight\" rating and a target price of HK$130. The report indicates that China's...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","LU2242644610.SGD","LU2097828805.USD","BK1583","LU2328871848.SGD","BK1161","01801","HK0000165453.HKD","LU0502904849.HKD","BK1589","LU2097828474.EUR","LU2097828631.EUR","LU2488822045.USD","LU2097828714.EUR","LU1969619763.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2616899223","title":"Innovent Biologics Says Lymphoma Drug Bags China Nod for Additional Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2616899223","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616899223?lang=en_us&edition=fundamental","pubTime":"2026-03-02 15:56","pubTimestamp":1772438183,"startTime":"0","endTime":"0","summary":"Innovent Biologics  said Jaypirca, or pirtobrutinib, obtained approval for a new indication from China's National Medical Products Administration, according to a Feb. 27 Hong Kong bourse filing.Shares of the drug company were down nearly 4% in Monday afternoon trading.The new indication is for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.In China, pirtobrutinib was developed by Eli Lilly and Company and is commercialized in mainland China by Innovent Biologics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828714.EUR","LU1969619763.USD","BK1589","LU2097828805.USD","BK1161","LU2097828557.USD","LU2488822045.USD","BK1583","LU2097828474.EUR","LU2242644610.SGD","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","01801","HK0000165453.HKD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2616877685","title":"Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616877685?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:00","pubTimestamp":1772409600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUABM960D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","BK1589","BK1161","LU2328871848.SGD","01801","LU0502904849.HKD","LU2097828631.EUR","LU2242644610.SGD","HK0000165453.HKD","BK1583","LU0455707207.USD","LU2097828474.EUR","LU2097828714.EUR","LU2097828557.USD"],"gpt_icon":0},{"id":"2614328850","title":"BRIEF-Innovent Biologics Says Jaypirca Received Approval By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2614328850","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614328850?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:25","pubTimestamp":1772205922,"startTime":"0","endTime":"0","summary":"BRIEF-Innovent Biologics Says Jaypirca Received Approval By NMPA ChinaFeb 27 (Reuters) - Innovent Biologics Inc 1801.HK:JAYPIRCA RECEIVED APPROVAL BY NMPA CHINAFurther company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","BK1589","BK1161","LU2328871848.SGD","01801","LU0502904849.HKD","LU2097828631.EUR","LU2242644610.SGD","HK0000165453.HKD","BK1583","LU0455707207.USD","LU2097828474.EUR","LU2097828714.EUR","LU2097828557.USD"],"gpt_icon":0},{"id":"1180048841","title":"Innovent Biologics, Inc. (1801) Announces NMPA Approval of Jaypirca for Recurrent CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=1180048841","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180048841?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:43","pubTimestamp":1772192595,"startTime":"0","endTime":"0","summary":"Innovent Biologics, Inc. (1801) announced that Jaypirca (pirtobrutinib), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, has gained approval from the National Medical Products Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"1192198269","title":"INNOVENT BIO's Pirtobrutinib Gains Approval in China for Relapsed or Refractory CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=1192198269","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192198269?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:42","pubTimestamp":1772192567,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) announced that the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Pirtobrutinib, has received approval from China's National Medical Products Administration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","LU2097828474.EUR","BK1583","LU2097828805.USD","01801","LU2097828557.USD","LU2242644610.SGD","LU2328871848.SGD","LU2488822045.USD","BK1589","BK1161","LU2097828714.EUR","LU1969619763.USD","LU0455707207.USD","HK0000165453.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2614372438","title":"Innovent Biologics - Jaypirca Received Approval by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2614372438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614372438?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:32","pubTimestamp":1772191974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0502904849.HKD","LU2097828474.EUR","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","LU2097828631.EUR","LU1969619763.USD","01801","LU2328871848.SGD","LU0455707207.USD","BK1161","BK1583","LU2097828805.USD","BK1589","HK0000165453.HKD"],"gpt_icon":0},{"id":"2614837241","title":"Innovent Says China NMPA Approves Jaypirca for Relapsed or Refractory CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2614837241","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614837241?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:32","pubTimestamp":1772191969,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. said China’s National Medical Products Administration has approved Jaypirca , a non-covalent BTK inhibitor, for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior systemic therapy including a BTK inhibitor. The company said the approval was supported by results from the Phase 3 BRUIN CLL-321 trial comparing pirtobrutinib with investigator’s choice regimens. Innovent said pirtobrutinib is developed by Eli Lilly and Company and commercialized in mainland China by Innovent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer In","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLJyr0h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0005OL40V9.USD","LU2328871848.SGD","LU0823434740.USD","LU1064131342.USD","LU2756315664.SGD","SG9999013999.USD","LU2750360997.AUD","LU0316494557.USD","LU2168564149.EUR","LU2097828631.EUR","LU2491050154.USD","LU2602419157.SGD","01801","LU2168564222.USD","LU2237443622.USD","LU1232071149.USD","SG9999017495.SGD","LU0943347566.SGD","IE00BFSS7M15.SGD","LU2023250504.SGD","IE00B4R5TH58.HKD","LU2264538146.SGD","LU2357305700.SGD","LU2746668974.SGD","IE00B2B36J28.USD","LU1093756168.USD","LU2108987350.USD","LU2750360641.GBP","LU0823416689.USD","LU0109394709.USD","LU0097036916.USD","IE00BN29S564.USD","LU1629891620.HKD","BK4516","LU0289739699.SGD","SG9999015952.SGD","LU1989771016.USD","LU1280957306.USD","LU1804176565.USD","LU2112291526.USD","SGXZ81514606.USD","LU2471134952.CNY","LU1366192091.USD","IE00BK4W5M84.HKD","LU0320765059.SGD","LU0225283273.USD","IE00BKPKM429.USD","LU0158827948.USD","IE0009355771.USD","SG9999014906.USD","ELIL","LU0320765992.SGD","LU0106261372.USD","LU0198837287.USD","LU1145028129.USD","BK4533","LU2168564495.EUR","LU1023059063.AUD","LLII","IE00BJT1NW94.SGD","LU0353189763.USD","LU2097828474.EUR","LLYZ","BK4588","BK4599","LU0238689110.USD","LU0256863902.USD","LU0353189680.USD","LU0708995401.HKD","LU2461242641.AUD","BK4585","LU0689472784.USD","LU2242644610.SGD","SG9999014880.SGD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","LU1093756325.SGD","LU2111349929.HKD","LU0456855351.SGD","LU2237443895.HKD","LU2417539215.USD","LU0203202063.USD","SGXZ51526630.SGD","IE00BJJMRX11.SGD","LU1057294990.SGD","LU2471134796.USD","IE0004445239.USD","LU1917777945.USD","LU2265009873.SGD","LU2491050071.SGD","LU2089984988.USD","IE00B1XK9C88.USD","LU0820561909.HKD","LU0820562030.AUD","LU2237443549.SGD","LU1720051017.SGD","IE0001KFT4U8.USD","LU1548497426.USD","LU2087625088.SGD","LU2462157665.USD","IE0002141913.USD","IE00BKDWB100.SGD","LU2324357040.USD","LU2237438978.USD","LU2271345857.HKD","LU2471134879.HKD","LU0471298777.SGD","LU0417517546.SGD","LU0203201768.USD","LU2106854487.HKD","BK1583","LU2896262040.SGD","SG9999018865.SGD","LU0820561818.USD","LU2211815571.USD","IE00BWXC8680.SGD","LU2552382215.SGD","LU2756315318.SGD","LU0158827781.USD","LU0006306889.USD","LU0210536198.USD","LU0466842654.USD","LU0882574139.USD","LU1551013425.SGD","LU0061475181.USD","LU2361045086.USD","LU1720051108.HKD","LU1291159041.SGD","SG9999018857.SGD","LU2746668461.USD","LU1988902786.USD","LU0234572021.USD","LU2491049909.HKD","LU1868837136.USD","LU1323610961.USD","LU2028103732.USD","LU1061106388.HKD","LU2237443978.SGD","LU0094547139.USD","LU0787776722.HKD","LU2097828805.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU2097828557.USD","SG9999001176.USD","LU0079474960.USD","LU1267930730.SGD","SG9999015945.SGD","SGXZ57979304.SGD","LU2089284900.SGD","BK4581","LU0964807845.USD","LU2097828714.EUR","LU0114720955.EUR","LU2237443382.USD","SG9999001176.SGD","LU0823434583.USD","LU0354030511.USD","LU1983299246.USD","LLYX","SGXZ31699556.SGD","SG9999014898.SGD","LU2360106947.USD","LU2456880835.USD","LU0889565916.HKD","LU0432979614.USD","LU1712237335.SGD","LU2168564065.EUR","BK1161","LU2213496289.HKD","BK1589","LU2552382058.USD","SG9999015986.USD","LU2361044865.SGD","LU0096364046.USD","LU2237443465.HKD","LU0683600562.USD","LU1551013342.USD","LU0256863811.USD","HK0000165453.HKD","LU1868836591.USD","LU0640476718.USD","LU2089283258.USD","LU1969619763.USD","IE00B775H168.HKD","LU0672654240.SGD","LU0502904849.HKD","LU0354030438.USD","BK4534","LU1069344957.HKD","LU1868837300.USD","LU2023250330.USD","ELIS","IE00B4JS1V06.HKD","BK4007","LU1127390331.HKD","LU0122379950.USD","LU0882574055.USD","LU0266013472.USD","IE0004445015.USD","LU2023251221.USD","IE00BJLML261.HKD","IE00B7KXQ091.USD","LU0471298694.HKD","LU2552382132.HKD","LU0109391861.USD","LU2361044949.HKD","IE00BFTCPJ56.SGD","IE00BJJMRY28.SGD","LU2468319806.SGD","SGXZ99366536.SGD","LU0385154629.USD","GB00BDT5M118.USD","LU1868836914.USD","LU1868836757.USD","LU2063271972.USD","LU0455707207.USD","LU0058720904.USD","IE00BK4W5L77.USD","LU2236285917.USD","SG9999014914.USD","LU1035775433.USD","LU1814569148.SGD","SG9999015978.USD","BK1147","LU0786609619.USD","LU2168563687.JPY","LU2471134523.USD","LU0323591593.USD","LU2488822045.USD","LU1623119135.USD"],"gpt_icon":0},{"id":"2612877694","title":"A Look At Innovent Biologics (SEHK:1801) Valuation After Progress In Phase 3 IBI354 Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612877694","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612877694?lang=en_us&edition=fundamental","pubTime":"2026-02-17 04:15","pubTimestamp":1771272945,"startTime":"0","endTime":"0","summary":"Innovent Biologics (SEHK:1801) has caught investor attention after dosing the first participant in its pivotal Phase 3 HeriCare-Breast01 trial for IBI354, a HER2-directed antibody drug conjugate in breast cancer.\nSee our latest analysis for Innovent Biologics.\nThat Phase 3 milestone comes on the back of an eventful few weeks, including a new collaboration with Eli Lilly and strong 2025 product revenue figures. The share price has a year to date return of 13.07% alongside a 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/a-look-at-innovent-biologics-sehk1801-valuation-after-progre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/a-look-at-innovent-biologics-sehk1801-valuation-after-progre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU2328871848.SGD","PRGS","LU2242644610.SGD","LU2097828631.EUR","LU2097828474.EUR","BK4097","BK1161","LU1969619763.USD","LU2097828805.USD","LU2065732104.USD","HK0000165453.HKD","BK1589","LU2097828714.EUR","LU0455707207.USD","01801","LU0502904849.HKD","BK1583","LU2488822045.USD","LU2097828557.USD"],"gpt_icon":0},{"id":"2611190152","title":"Innovent Biologics Doses First Patient in Phase 3 Trial of Novel HER2 ADC for Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611190152","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611190152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:00","pubTimestamp":1770940820,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the initiation of a pivotal Phase 3 clinical study, HeriCare-Breast01, evaluating IBI354—a HER2 monoclonal antibody-camptothecin derivative conjugate —as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The first participant has been successfully dosed in this study in China. IBI354 is also being investigated in another ongoing pivotal Phase 3 trial, HeriCare-Ovarian01. Early-stage studies have demonstrated a favorable safety and efficacy profile for IBI354, but the results of the current Phase 3 trial have not yet been presented and are anticipated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7Y3cHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU1969619763.USD","BK1589","BK1147","LU2097828805.USD","BK1161","01911","LU2097828557.USD","LU2488822045.USD","BK1583","LU2097828474.EUR","LU2242644610.SGD","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","01801","HK0000165453.HKD","LU0502904849.HKD"],"gpt_icon":0},{"id":"1197317413","title":"JPMorgan Increases Stake in Innovent Bio by 585,900 Shares at HK$79.23 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1197317413","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197317413?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:24","pubTimestamp":1770895467,"startTime":"0","endTime":"0","summary":"On February 6, JPMorgan purchased an additional 585,900 shares of Innovent Bio (01801) at HK$79.232 per share, amounting to approximately HK$46.422 million. Following this transaction, the financial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","LU0455707207.USD","LU0496365809.HKD","LU0211327993.USD","IE00B3S45H60.SGD","LU1116320901.HKD","HK0000165453.HKD","IE00B1BXHZ80.USD","LU0971096721.USD","LU2097828557.USD","LU2552382132.HKD","LU2746668974.SGD","LU0345770308.USD","LU0211331839.USD","LU0265550359.USD","LU0640476718.USD","LU2023250330.USD","LU2505996681.GBP","LU2430703251.USD","LU1145028129.USD","LU0820562030.AUD","BK4534","LU0345770993.USD","LU0006306889.USD","IE00BKVL7J92.USD","LU1894683348.USD","BK1161","LU2552382058.USD","LU1670627923.USD","LU2462157665.USD","LU0170899867.USD","LU0976567544.SGD","LU1670628061.USD","LU2097828805.USD","IE000M9KFDE8.USD","LU2237443895.HKD","LU0320765489.SGD","LU1974910355.USD","IE00BHPRN162.USD","BK4504","BK4516","LU1894683264.USD","LU1969619763.USD","IE00BKDWB100.SGD","IE00BYXW3230.USD","LU1551013342.USD","LU0943347566.SGD","LU2213496289.HKD","LU0208291251.USD","LU1244550494.USD","LU0868494617.USD","LU1917777945.USD","LU2505996509.AUD","SG9999002232.USD","LU1366192091.USD","LU0787776722.HKD","LU2488822045.USD","BK4585","IE00BJTD4N35.SGD","LU1162221912.USD","IE00BDRTCR15.USD","IE00BZ1G4Q59.USD","LU0215105999.USD","LU2023250843.SGD","LU1551013425.SGD","LU1244550221.USD","IE00BJLML261.HKD","LU0203345920.USD","IE00BFXG1179.USD","LU2242644610.SGD","BK4588","BK4533","LU2237443465.HKD","LU2430703178.SGD","IE00BBT3K403.USD","LU2054465674.USD","LU2237443622.USD","LU0203347892.USD","LU1032466523.USD","LU0320765646.SGD","LU1720051017.SGD","LU0689472784.USD","LU0149725797.USD","LU0882574139.USD","LU1720051108.HKD","LU2236285917.USD","LU1914381329.SGD","LU0265550946.USD","LU0964807845.USD","LU0238689110.USD","IE00BN8TJ469.HKD","LU2097828714.EUR","LU2746668461.USD","LU0820561818.USD","BK1589","LU0345769631.USD","IE00BJTD4V19.USD","BK4550","LU0310799852.SGD","LU0267386448.USD","LU2264538146.SGD","LU2417539215.USD","LU2106854487.HKD","BK4566","LU1261432733.SGD","JPM","LU0106261372.USD","IE00BDCRKT87.USD","IE00B775SV38.USD","LU0683600562.USD","IE0034235295.USD","IE00BLSP4452.SGD","LU1548497426.USD","LU2756315664.SGD","LU1119994496.HKD","LU0251132253.USD","LU0256863811.USD","LU0323591593.USD","LU0820561909.HKD","LU0106831901.USD","LU2592432038.USD","LU2097828631.EUR","LU2756315318.SGD","LU2430703095.HKD","LU1116320737.USD","LU1496350171.SGD","LU2381873111.SGD","LU1629891620.HKD","LU1496350502.SGD","IE00BLSP4239.USD","LU1988902786.USD","LU1244550577.SGD","01801","LU0234572021.USD","LU1363072403.SGD","LU0070302665.USD","LU1084165304.USD","BK4581","LU2237443978.SGD","LU2097828474.EUR","LU2328871848.SGD","IE00BWXC8680.SGD","LU0417517546.SGD","BK4207","LU0211328371.USD","LU2237443382.USD","LU2552382215.SGD","LU1267930490.SGD","LU2023250504.SGD","LU0211326839.USD","LU1668664300.SGD","LU0211326755.USD","LU2456880835.USD","LU2242649171.HKD","LU0345769128.USD","IE00B1XK9C88.USD","LU0048584097.USD","IE0034235188.USD","LU2211815571.USD","LU2357305700.SGD","LU1064131342.USD","LU0868494708.USD","LU0942090050.USD","BK1583","SG9999002224.SGD","LU0502904849.HKD","LU2237443549.SGD","IE0034235303.USD"],"gpt_icon":0},{"id":"1131197562","title":"Innovent Biologics Forges Seventh Partnership with Eli Lilly in $8.85 Billion Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1131197562","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131197562?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:01","pubTimestamp":1770724910,"startTime":"0","endTime":"0","summary":"A golden cross signal has formed on the MACD indicator, and certain stocks are performing well.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU2236285917.USD","IE00B775H168.HKD","LU2471134796.USD","LU2097828805.USD","LU2417539215.USD","SGXZ51526630.SGD","IE00BKDWB100.SGD","LU1035775433.USD","SG9999014914.USD","LU0787776722.HKD","LU0320765992.SGD","LU1712237335.SGD","IE00BK4W5L77.USD","LU0354030511.USD","LU2491050154.USD","LU2602419157.SGD","SG9999017495.SGD","LU0786609619.USD","LU1969619763.USD","LU2168564495.EUR","LU0061475181.USD","LU0058720904.USD","LU0882574055.USD","LU2468319806.SGD","BK4588","LU0502904849.HKD","IE00B1BXHZ80.USD","LU0823434583.USD","BK4007","LU0640476718.USD","LU1868837136.USD","LU2471134952.CNY","LU1232071149.USD","BK4581","LU2328871848.SGD","IE00B4JS1V06.HKD","LU0097036916.USD","ELIL","HK0000165453.HKD","IE00BFTCPJ56.SGD","LU1323610961.USD","SG9999015952.SGD","SGXZ99366536.SGD","LU0820562030.AUD","LU2168564065.EUR","SGXZ81514606.USD","LU0683600562.USD","LU1868836757.USD","LU0353189680.USD","LU2023251221.USD","LU2462157665.USD","LU2089284900.SGD","SG9999018857.SGD","SGXZ57979304.SGD","LU1983299246.USD","LU1127390331.HKD","LU0198837287.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0316494557.USD","LU0823416689.USD","LU1291159041.SGD","LU1093756168.USD","LU0006306889.USD","LU1267930730.SGD","LU2237443549.SGD","IE0004445239.USD","LU2237443622.USD","IE0005OL40V9.USD","LU2097828557.USD","LU2097828631.EUR","IE00B1XK9C88.USD","LU1057294990.SGD","BK1583","BK4599","BK4516","LU0708995401.HKD","LU2361044949.HKD","SG9999015945.SGD","SG9999014906.USD","SG9999015978.USD","LU0432979614.USD","SG9999013999.USD","IE00BWXC8680.SGD","LLYX","LU0385154629.USD","LU0820561818.USD","IE00BKPKM429.USD","LU2491050071.SGD","LU0820561909.HKD","LU2063271972.USD","LU2023250504.SGD","LU1804176565.USD","LU0238689110.USD","IE0009355771.USD","LU2756315664.SGD","IE00B4R5TH58.HKD","LU0106261372.USD","LU2089984988.USD","BK1589","LU0289739699.SGD","LU1366192091.USD","LU2108987350.USD","LU2271345857.HKD","IE00BFSS8Q28.SGD","LU2265009873.SGD","LU2471134523.USD","LU1720051017.SGD","LU1023059063.AUD","LU2028103732.USD","SG9999014880.SGD","IE00BN29S564.USD","LU2361044865.SGD","LU0354030438.USD","LU1061106388.HKD","LU0266013472.USD","LU0456855351.SGD","IE00B7KXQ091.USD","BK1574","LU1629891620.HKD","SG9999001176.USD","LU2264538146.SGD","LU0943347566.SGD","LU0079474960.USD","LU2456880835.USD","LU2756315318.SGD","LU2324357040.USD","IE0004445015.USD","LU1868836591.USD","LU1548497426.USD","LU0094547139.USD","LU0471298694.HKD","LU2168564149.EUR","LU2097828714.EUR","SG9999001176.SGD","LU1814569148.SGD","IE00BJT1NW94.SGD","LU0353189763.USD","LU1623119135.USD","LU2237443465.HKD","LU2488822045.USD","LU2750360997.AUD","LU2168563687.JPY","LU1868836914.USD","BK4534","LU0109394709.USD","LU1974910355.USD","LU2168564222.USD","LU2237443382.USD","LU0114720955.EUR","LU2360106947.USD","LU2896262040.SGD","LU0096364046.USD","ELIS","IE00BK4W5M84.HKD","LU0823434740.USD","LU1989771016.USD","LU2552382132.HKD","LU0471298777.SGD","LU0203202063.USD","LLYZ","LU0109391861.USD","LU0689472784.USD","LU2552382215.SGD","LU1064131342.USD","GB00BDT5M118.USD","LU1093756325.SGD","LU2089283258.USD","LU0158827781.USD","LU0466842654.USD","LU1551013342.USD","LU0210536198.USD","LU0122379950.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU0256863811.USD","LU2211815571.USD","LU0234572021.USD","LU0672654240.SGD","LU2097828474.EUR","LU2461242641.AUD","LU0256863902.USD","LU1069344957.HKD","LU2750360641.GBP","LU2237443895.HKD","LU2746668461.USD","LU2746668974.SGD","LU0455707207.USD","LU1917777945.USD","LU2361045086.USD","SG9999014898.SGD","LU1868837300.USD","LU2357305700.SGD","LU2552382058.USD","SG9999015986.USD","SGXZ31699556.SGD","LU0320765059.SGD","LU2106854487.HKD","LU0417517546.SGD","LU0882574139.USD","IE00BFSS7M15.SGD","LU2023250330.USD","BK4533","LU1145028129.USD","LU2237443978.SGD","BK1161","LU2471134879.HKD","IE00BJJMRY28.SGD","BK4585","LU0158827948.USD","LU2491049909.HKD","LU0323591593.USD","LU1720051108.HKD","LU2242644610.SGD","LU1551013425.SGD","LU1280957306.USD","LU2237438978.USD","LLY","LU1988902786.USD","LU2213496289.HKD","LU0964807845.USD","LU2111349929.HKD","01801","LU0225283273.USD","LU2087625088.SGD","SG9999018865.SGD","IE00BJLML261.HKD","IE00BJJMRX11.SGD","LU0203201768.USD"],"gpt_icon":0},{"id":"2610769727","title":"Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2610769727","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610769727?lang=en_us&edition=fundamental","pubTime":"2026-02-10 13:18","pubTimestamp":1770700680,"startTime":"0","endTime":"0","summary":"0518 GMT - Innovent is on track to become a leading biopharmaceutical company in China, Deutsche Bank analyst Cyrus Ng says in a note. Ng notes the management is confident in achieving its 2027 revenue target of CNY 20 billion. He adds that the company appears on course to reach its 2030 target of having more than five pipeline assets entering multi-regional Phase III trials. A key concern is the average sales pressures for its weight-loss drug, Mazdutide, he adds. \"We like the short term business growth potential of Innovent from its current product portfolio and the mid-term global expansion plan,\" says Ng. DB raises its target to HK$110 from HK$107 for its shares, which are 4.6% up at HK$89.35. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","01801","LU2488822045.USD","LU2097828805.USD","LU2097828557.USD","LU0455707207.USD","LU2097828474.EUR","LU1969619763.USD","LU2097828631.EUR","BK1161","LU0502904849.HKD","LU2328871848.SGD","HK0000165453.HKD","LU2097828714.EUR","LU2242644610.SGD"],"gpt_icon":0},{"id":"1173096749","title":"INNOVENT BIO Shares Climb Over 5% Again Following Seventh Global Partnership with Eli Lilly; Goldman Sachs Sees Undervaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1173096749","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173096749?lang=en_us&edition=fundamental","pubTime":"2026-02-10 10:23","pubTimestamp":1770690208,"startTime":"0","endTime":"0","summary":"INNOVENT BIO (01801) rose more than 5% again, climbing 5.56% to HK$90.1 by the time of writing, with a turnover of HK$603 million. The increase follows the company's recent announcement of its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"68db43c16767d304ca65eff8dc9eddd8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","LU0203201768.USD","LU2746668974.SGD","LU2361045086.USD","LU2756315318.SGD","LU0672654240.SGD","LU0061475181.USD","LU2108987350.USD","LU0820561818.USD","LU1720051108.HKD","LU2168564149.EUR","GB00BDT5M118.USD","SG9999014914.USD","BK4534","IE0004445239.USD","IE0004445015.USD","IE00BJT1NW94.SGD","LU0320765059.SGD","LU2023250504.SGD","LU2097828474.EUR","BK4127","LU0256863811.USD","LU2357305700.SGD","LU2456880835.USD","LU2264538146.SGD","LU0640476718.USD","SG9999001176.SGD","LU1057294990.SGD","LU2746668461.USD","SG9999015952.SGD","LU2242644610.SGD","LU0210536198.USD","IE0009355771.USD","LU2211815571.USD","SGXZ31699556.SGD","01801","IE00BJLML261.HKD","LU2168564495.EUR","LU2361044865.SGD","IE0002141913.USD","LU0079474960.USD","LU1791807156.HKD","SG9999017495.SGD","SG9999018857.SGD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0820562030.AUD","LU1323610961.USD","LU1969619763.USD","LU0006306889.USD","LU1551013425.SGD","LU2750360641.GBP","LU2168563687.JPY","IE0005OL40V9.USD","LU2023251221.USD","LU2089284900.SGD","LU1551013342.USD","LU2089984988.USD","BK1583","LU0708995401.HKD","LU1988902786.USD","IE00B4JS1V06.HKD","IE00BK4W5L77.USD","IE0004091025.USD","SG9999018865.SGD","LU0320765992.SGD","BK4550","LU1720051017.SGD","LU2756315664.SGD","LU1069344957.HKD","LU1668664300.SGD","LU0502904849.HKD","LU1093756168.USD","LU2023250330.USD","LU2237443382.USD","SG9999015978.USD","LU0256863902.USD","LU2491050071.SGD","LU2491049909.HKD","LU0353189680.USD","LU0251131958.USD","LU1061106388.HKD","IE00B1BXHZ80.USD","LU1629891620.HKD","LU0266013472.USD","SG9999015945.SGD","IE00BN29S564.USD","BK4552","LU0238689110.USD","LU2111349929.HKD","LU0689472784.USD","LU1868836757.USD","SG9999014880.SGD","LU0683600562.USD","SGXZ81514606.USD","LU0106261372.USD","LU2552382215.SGD","BK4516","IE00BJJMRY28.SGD","IE00BFTCPJ56.SGD","LU2168564065.EUR","LU0742534661.SGD","LU2360106947.USD","ELIL","LU0109394709.USD","LU2236285917.USD","LU2168564222.USD","BK4599","LU1868837136.USD","LU0198837287.USD","LU0455707207.USD","LU1366192091.USD","LU0122379950.USD","LU0417517546.SGD","LU2237438978.USD","LU2097828805.USD","LU2471134879.HKD","LU1280957306.USD","LU2471134523.USD","LU1868837300.USD","LU0787776722.HKD","SGXZ51526630.SGD","LU1035775433.USD","LU0097036916.USD","IE0034235188.USD","LU2271345857.HKD","SG9999014906.USD","LU0345770993.USD","IE00BWXC8680.SGD","SG9999001176.USD","ELIS","LU0471298694.HKD","LU0882574139.USD","LU1974910355.USD","IE00BJJMRX11.SGD","BK1161","LU0094547139.USD","IE00B4R5TH58.HKD","LU0823434583.USD","LU1127390331.HKD","LU1983299246.USD","LU2087625088.SGD","LU2106854487.HKD","IE00B7KXQ091.USD","LU0158827948.USD","BK4533","LU0114720955.EUR","LU0466842654.USD","LU2328871848.SGD","SG9999015986.USD","LU1093756325.SGD","LU2028103732.USD","LU1814569148.SGD","LU0106831901.USD","LU2237443622.USD","LU1623119135.USD","LU0964807845.USD","LU0345770308.USD","LU0203202063.USD","LU0234572021.USD","LU0943347566.SGD","LU2089283258.USD","LU2468319806.SGD","LU2602419157.SGD","IE00BKDWB100.SGD","LU2462157665.USD","IE00BKPKM429.USD","LU2265009873.SGD","LLYX","LU2237443978.SGD","LU0323591593.USD","LU0432979614.USD","IE00B775H168.HKD","LU1804176565.USD","IE0004086264.USD","LU0096364046.USD","GSX","LU1291159041.SGD","LU0251142724.SGD","LU0158827781.USD","LU1548497426.USD","BK4504","LU1023059063.AUD","LU0048573561.USD","IE00BFSS8Q28.SGD","LU1145028129.USD","LU2488822045.USD","LU2237443895.HKD","LU2896262040.SGD","LU0353189763.USD","LU2471134952.CNY","SGXZ57979304.SGD","LU0823416689.USD","LU2552382058.USD","BK1589","IE00BJJMRZ35.SGD","LU1712237335.SGD","LU2361044949.HKD","IE00B19Z3581.USD","LU2237443549.SGD","LU2237443465.HKD","LU2097828631.EUR","LU2097828714.EUR","LU1868836914.USD","IE00BK4W5M84.HKD","LU2324357040.USD","SGXZ99366536.SGD","LU0109391861.USD","IE00B1XK9C88.USD","LU2461242641.AUD","LU1894683264.USD","LU1232071149.USD","SG9999014898.SGD","LU0786609619.USD","BK4581","IE0002270589.USD","LU2112291526.USD","BK4588","LU0820561909.HKD","LU0058720904.USD","BK4585","LU0354030438.USD","LU0225283273.USD","LU1267930730.SGD","LU2491050154.USD","LU2552382132.HKD","LU0456855351.SGD","LU0316494557.USD","LU0882574055.USD","HK0000165453.HKD","LU0471298777.SGD","LU1894683348.USD","LU1917777945.USD","LU2063271972.USD","LU2097828557.USD","LU2213496289.HKD","LU2750360997.AUD","BK4007","IE00BFXG1179.USD","LU0823434740.USD","LU0385154629.USD","LU2417539215.USD","LU2471134796.USD","IE00BFSS7M15.SGD","IE00B2B36J28.USD","LLYZ","LU1064131342.USD","LU1989771016.USD","LU0354030511.USD","LU0289739699.SGD","LU0889565916.HKD","SG9999013999.USD"],"gpt_icon":0},{"id":"2610664079","title":"Asian Market Stocks Trading Below Estimated Value In February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664079","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610664079?lang=en_us&edition=fundamental","pubTime":"2026-02-10 06:07","pubTimestamp":1770674856,"startTime":"0","endTime":"0","summary":"As global markets grapple with volatility, driven by concerns over artificial intelligence and geopolitical tensions, investors are increasingly turning their attention to value-oriented segments that may offer more stability. In this context, identifying undervalued stocks in the Asian markets can present unique opportunities for those seeking to capitalize on potential discrepancies between a stock's market price and its estimated intrinsic value.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9621091-choice1-main-header/1585186722323","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9621091-choice1-main-header/1585186722323"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/tw/tech/tpex-3324/auras-technology-shares/news/asian-market-stocks-trading-below-estimated-value-in-februar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/tw/tech/tpex-3324/auras-technology-shares/news/asian-market-stocks-trading-below-estimated-value-in-februar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1969619763.USD","LU2097828631.EUR","LU0455707207.USD","LU2097828474.EUR","01801","BK1589","BK1583","BK8049","CVT.NZ","LU2097828714.EUR","LU2242644610.SGD","LU2328871848.SGD","HK0000165453.HKD","LU2488822045.USD","BK1161","LU2097828805.USD","LU0502904849.HKD","LU2097828557.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":-0.0982},{"period":"3month","weight":-0.0511},{"period":"6month","weight":-0.1737},{"period":"1year","weight":1.0573},{"period":"ytd","weight":0.0603}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.066},{"period":"3month","weight":-0.0197},{"period":"6month","weight":-0.035},{"period":"1year","weight":0.0854},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.025289},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"INNOVENT BIO","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOVENT BIO,01801,INNOVENT BIO股票,INNOVENT BIO股票老虎,INNOVENT BIO股票老虎国际,INNOVENT BIO行情,INNOVENT BIO股票行情,INNOVENT BIO股价,INNOVENT BIO股市,INNOVENT BIO股票价格,INNOVENT BIO股票交易,INNOVENT BIO股票购买,INNOVENT BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOVENT BIO(01801),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOVENT BIO(01801) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}